TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of
TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including
therapy.